









Markets
/
Stocks
/
nasdaq-orka
/

Oruka Therapeutics Inc

ORKA

33.050USD

+1.630+5.19%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.60BMarket Cap

47.53P/E TTM



Oruka Therapeutics Inc

33.050

+1.630+5.19%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Oruka Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Oruka Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 56.85.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Oruka Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

65 / 392

Overall Ranking

185 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Oruka Therapeutics Inc Highlights

StrengthsRisks

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is 47.53, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 48.06M shares, increasing 16.58% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 584.39K shares of this stock.

Analyst Rating

Based on 14 analysts

Strong Buy

Current Rating

56.846

Target Price

+72.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Oruka Therapeutics Inc is 5.81, ranking 322 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.81

Change



Financials

3.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Oruka Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Oruka Therapeutics Inc is 6.50, ranking 264 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 47.53, which is 7.50% below the recent high of 51.09 and 127.11% above the recent low of -12.88.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Oruka Therapeutics Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 46.00, with a high of 63.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Strong Buy

Current Rating

56.846

Target Price

+72.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Oruka Therapeutics Inc

ORKA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Oruka Therapeutics Inc is 9.20, ranking 30 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 37.55 and the support level at 27.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.97

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.623

Neutral

RSI(14)

52.227

Neutral

STOCH(KDJ)(9,3,3)

27.448

Neutral

ATR(14)

2.061

High Vlolatility

CCI(14)

-141.498

Sell

Williams %R

64.492

Sell

TRIX(12,20)

0.559

Sell

StochRSI(14)

46.023

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

33.264

Sell

MA10

33.999

Sell

MA20

33.269

Sell

MA50

31.172

Buy

MA100

27.645

Buy

MA200

20.263

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.24M

+28.86%

VR Adviser, LLC

4.15M

Fairmount Funds Management LLC

3.71M

+9.89%

Viking Global Investors LP

Star Investors

2.67M

Deep Track Capital LP

2.65M

+38.36%

The Vanguard Group, Inc.

Star Investors

1.78M

-2.24%

BlackRock Institutional Trust Company, N.A.

2.01M

+10.05%

RTW Investments L.P.

1.95M

Commodore Capital LP

1.75M

+23.48%

Braidwell LP

1.38M

-9.34%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Oruka Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is -0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.